Patrick Soon-Shiong's Nant Takes Board Seats at PDS Biotech
Nant Capital is putting in roughly $11.5 million at the initial close, with another $11 million tied to a clinical trial filing. It also paid $25,000 for a year of exclusive access to the company's HPV cancer vaccine program.